SL-401
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 72 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Stemline Therapeutics, Inc.
- Tags
- Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), CD123
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1536
- NCT Identifier
- NCT03113643
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.